Is HIMS or INDV more undervalued in 2026?

CirclFi compares Hims & Hers Health, Inc. (HIMS) and Indivior Pharmaceuticals, Inc. (INDV) using 13 institutional-grade valuation models. HIMS has a Quality of Company score of 6.7/10 while INDV scores 5.9/10.

Which is a better buy — HIMS or INDV?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HIMS and INDV valuations compare?

HIMS at $25.38 and INDV at $36.61 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HIMS vs INDV Valuation Comparison 2026 — Intrinsic Value Analysis

HIMS

Drug Manufacturers - Specialty & Generic

Hims & Hers Health, Inc.

Quality

6.7

out of 10

Value Trap

LOW

Price

$25.38

Last close

Models

12/13

Active

INDV

Drug Manufacturers - Specialty & Generic

Indivior Pharmaceuticals, Inc.

Quality

5.9

out of 10

Value Trap

SAFE

Price

$36.61

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	HIMS Fair Value	HIMS Upside	INDV Fair Value	INDV Upside
Bayesian DCF	Intrinsic	$14.62	-42.4%	$8.36	-77.2%
Earnings Power Value	Intrinsic	$3.51	-87.6%	$18.45	-49.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HIMS vs INDV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HIMS vs INDV — Which Stock Is More Undervalued?

HIMS scores higher with a 6.7/10 quality rating vs INDV's 5.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Hims & Hers Health, Inc. (HIMS) and Indivior Pharmaceuticals, Inc. (INDV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HIMS currently trades at $25.38 with a QOC of 6.7/10, while INDV trades at $36.61 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).